Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Karlas, Thomas; Petroff, David; Sasso, M.; Fan, Jian Gao; Mi, Yu; Lédinghen, Victor de; Kumar, Manoj; Lupșor-Platon, Monica; Han, Kwang Hyub; Cardoso, Ana Carolina; Ferraioli, Giovanna; Chan, Wah‐Kheong; Wong, Vincent W. S.; Myers, Robert P.; Chayama, Kazuaki; Friedrich‐Rust, Mireen; Beaugrand, Michel; Shen, Feng; Hiriart, Jean Baptiste; Sarin, Shiv Kumar; Badea, Radu; Jung, Kyu Sik; Marcellin, Patrick; Fı̀lice, Carlo; Mahadeva, Sanjiv; Wong, Grace Lai Hung; Crotty, Pam; Kitajima, Masaki; Bojunga, Joerg; Bédossa, Pierre; Keim, Volker; Wiegand, Johannes

doi:10.1016/j.jhep.2016.12.022

Cited by 783 publications

(878 citation statements)

References 53 publications

Supporting

Mentioning

808

Contrasting

Unclassified

Order By: Relevance

“…However, its diagnostic value has been confirmed in most aetiologies of chronic liver disease, including NAFLD. [24][25][26] All relevant confounding factors for the TE-based assessment of liver fibrosis induce false-high liver stiffness results leading to an overestimation of liver fibrosis stage. 27 Thus, they cannot explain the very low prevalence of liver fibrosis !F3 observed in our study.…”

Section: Discussionmentioning

confidence: 99%

Liver disease in adults with α1‐antitrypsin deficiency

et al. 2018

View full text Add to dashboard Cite

Background: The natural history of adult liver disease due to a1-antitrypsin deficiency (A1AD) remains poorly understood. Objective: We investigated whether heterozygosity for the Z-allele predisposes for the development of clinically significant portal hypertension (CSPH). Moreover, we aimed to non-invasively assess the prevalence of liver fibrosis and hepatic steatosis in adults with A1AD treated by pulmonologists. Methods: SERPINA1 rs28929474 (Z-allele) was genotyped in 315 patients with CSPH (hepatic venous pressure gradient !10 mmHg; cases) and 248 liver donors (controls). In addition, 31 adults with A1AD (Pi*ZZ/Pi*SZ) and 11 first-degree relatives (Pi*MZ/Pi*MS) underwent liver stiffness and controlled attenuation parameter (CAP) measurement. Results: Heterozygosity for the Z-allele was observed in 6.7% of patients with CSPH and 2.8% of liver donors. Thus, harboring the Z-allele was associated with increased odds of CSPH (odds ratio: 2.47; 95% confidence interval: 1.03-5.9; P ¼ 0.042). Among Pi*ZZ/Pi*SZ patients, 23%/3% had liver stiffness values indicative of liver fibrosis ( !F2/ !F3). Interestingly, 65%/52% of Pi*ZZ/Pi*SZ patients had CAP values indicative of hepatic steatosis ( !S1/ !S2). Conclusions: Heterozygosity for the Z-allele predisposes for the development of CSPH, confirming its role as a genetic (co)factor in liver disease. Pi*ZZ/SZ patients rarely develop liver fibrosis !F3 during adulthood; however, liver fibrosis !F2 is common. Elevated CAP values hint at underlying hepatic steatosis, which might promote liver fibrosis progression.

show abstract

Section: Discussionmentioning

confidence: 99%

Liver disease in adults with α1‐antitrypsin deficiency

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Whether these researches on SPIO will be translated into daily clinical practice remain unknown, due to the complexity of these procedures, and the emerging competing techniques such as Gd-EOB-DTPAenhanced MRI, improved ultrasound elastography, liver T1rho imaging etc. (132)(133)(134)(135).…”

Section: Spio Enhanced Liver Mrimentioning

confidence: 99%

A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging

Wáng

Idée

2017

Quant. Imaging Med. Surg.

184

116

View full text Add to dashboard Cite

show abstract

“…La casistica di Vuille-Lessard et al (37), per esempio, includeva il 20% di pazienti obesi e aveva rilevato una prevalenza di NAFLD del 48% usando il CAP mentre Guaraldi et al (20) avevano incluso solo il 4% dei pazienti obesi riportando una prevalenza del 36,9% utilizzando la TAC. Tale discrepanza potrebbe essere giustificata dal recente alert di ridotta specificità del CAP nei pazienti con BMI >30 (34,35). Una particolare attenzione andrebbe data agli studi condotti che utilizzano MRS, in quanto rappresenterebbe la nuova metodica non invasiva di elezione per valutare la NAFLD.…”

Section: Discussioneunclassified

“…L'elastografia epatica (Fibroscan), mediante la determinazione del parametro controllato di attenuazione (CAP), presenta una sensibilità/specificità superiori al 90% (33). Tuttavia, gli studi recenti che hanno confrontato CAP con MRS hanno riscontrato una minore specificità della CAP, soprattutto nei pazienti con alto indice di massa corporea (BMI) e/o diabete (34,35).…”

Section: Definizioni E Diagnosiunclassified

La steatosi epatica non alcolica in HIV: una revisione critica della letteratura.

Squillace¹,

Gori²,

Bandera³

2018

JHA

View full text Add to dashboard Cite

La steatosi epatica non alcolica in HIV:una revisione critica della letteratura. Non alcoholic fatty liver disease (NAFLD) and non alcoholic steatohepatitis (NASH) in HIV: a critical review. IntroduzioneLa steatosi epatica non alcolica (non alcoholic fatty liver disease, NAFLD) rappresenta una causa emergente di cirrosi e di carcinoma epatocellulare, a causa del diretto legame con l'insorgenza della steatoepatite non alcolica (NASH) (1, 2). La prevalenza di NAFLD nella popolazione generale è influenzata fortemente dall'area geografica di appartenenza, variando dal 7.1% in Nigeria (3) al 42% in Cina (4). Tali variazioni sarebbero imputabili sia a fattori genetici che a differenti regimi dietetici. Obesità, diabete mellito, dislipidemia e sindrome metabolica sono cause note di NAFLD primaria; il ruolo del genere e della razza non sono ancora ben definiti (5), sebbene sia stato rilevato un ruolo significativo del sesso maschile e della razza bianca

show abstract

Individual patient data meta-analysis of controlled attenuation parameter (CAP) technology for assessing steatosis

Cited by 783 publications

References 53 publications

Liver disease in adults with α1‐antitrypsin deficiency

Liver disease in adults with α1‐antitrypsin deficiency

A comprehensive literatures update of clinical researches of superparamagnetic resonance iron oxide nanoparticles for magnetic resonance imaging

La steatosi epatica non alcolica in HIV: una revisione critica della letteratura.

Contact Info

Product

Resources

About